Search
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: SILOPROST® 8, FENANTA® 8 MGPrasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalSimilar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. … As a result, inhibition of ADP-mediated platelet activation and aggregation occurs.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: PERKUNAL 5, PRASUGREL BETA 5 MG FTAEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … , resulting in a premature termination of the trial.
Categories: Heterocyclic Compounds, 2-RingProducts: DORVAK®, DORIPURE® 500Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigational[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … Ferumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [
Categories: Compounds used in a research, industrial, or household settingVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-olLacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … Lacosamide exhibits a stereoselective mode of interaction with sodium channels.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (R)-2-acetamido-N-benzyl-3- methoxypropionamide, (R)-LACOSAMIDE 1HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. … IPL 576,092 has previously been investigated as a treatment for asthma.
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: MORPHINAN-3,14-DIOL, 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-6-METHYLENE-, (5.ALPHA.)-, 17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol